TARGET MARKETS According to IMS Health.

TARGET MARKETS – According to IMS Health, oral antidiabetic belonged to treat non – insulin dependent diabetes, one of the largest therapeutic classes in 2005, of which insulin sensitizers represent the largest segment. In 2005, sales of marketed glitazones, the main drugs now than insulin sensitizers, amounted to more than $ 5 billion . SG Cowen estimates that in 2006 sales of glitazones is $ 6.2 billion exceed with a compound growth rate of 12 %, exceeding the compound growth rate of oral antidiabetics .

Pfizer recommends that physicians with about alternative therapies in the election. Arthritis and pain medication to their patients Celebrex remains one of these treatment options for osteoarthritis, rheumatoid arthritis and acute pain, and in accordance with good medical practice, should be the lowest effective dose for appropriate patients are administered.A pedagogical Videos showing the action of a Kork glass breaking and further information on eye safety and good eye health, see.